1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,196.04
USD
+10.17
- -
1.13TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
80.68
Basic EPS, GAAP
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
28.23
Free Cash Flow per Basic Share
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
11.58
Dividend per Share
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.24
Book Value per Share
15.84
15.47
15.11
15.2
13.86
11.73
5.76
8.81
10.02
11.19
12.13
15.75
28.01
33.62
Tangible Book Value per Share
11.92
9.68
4.99
5.22
3.11
8.25
-7.94
-5.64
-2.55
-0.53
-1.09
2.6
15.77
19.76
Basic Weighted Avg Shares
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
896
Sales/Revenue/Turnover
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
72,250
Operating Margin (%)
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
47.3
Depreciation Expense
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,043
Net Income, GAAP
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
25,277
Effective Tax Rate (%)
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
18.79
Profit Margin (%)
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
34.99
Working Capital
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
18,201
LT Debt
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
39,370
Total Equity
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
31,198
Return on Invested Capital (%)
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
41.09
Return on Capital (%)
21.27
10.43
10.21
11.15
-0.77
13.3
39.09
28.19
22.73
24.43
17.8
26.74
35.76
40.11
Return on Common Equity (%)
27.16
13.71
14.22
16.37
-1.3
24.27
94.66
88.81
62.08
61.86
48.65
84.57
105.31
110.39

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1,633
1,635
4,000
LT Borrowings
40,874
40,868
39,370
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
896
895
894
Market Capitalization
684,603
963,523
823,663

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
62,071
55,629
54,835
Cash, Cash Equivalents & STI
9,914
7,268
5,282
Accounts Receivable, Net
16,107
17,760
18,429
Inventories
12,180
13,744
14,529
Total Current Liabilities
40,141
35,228
36,634
Payables & Accruals
31,327
22,761
22,576
ST Debt
1,633
1,635
4,000
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
David A. Ricks
Full Time Employees
50,000
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lilly Corporate Center Indianapolis IN United States of America 46285
IPO Date
Jun 1, 1972
CIK
0000059478
Website
lilly.com
Similar Companies
Otsuka Holdings Co., Ltd. (4578.T)
Psyence Group Inc. (PSYG.CN)
Senores Pharmaceuticals Ltd. (SENORES.NS)
CSPC Pharmaceutical Group Limited (1093.HK)
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
Mayne Pharma Group Limited (MAYNF)
Business

Company News

APIChatGPT

  • investors.com

    Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts

  • 247wallst.com

    This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

  • zacks.com

    LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins

  • barrons.com

    As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

  • wsj.com

    Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

  • reuters.com

    Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

  • fool.com

    2 Top Growth Stocks to Buy Right Now Without Any Hesitation

  • youtube.com

    Lilly's Next-Generation Obesity Shot Clears Another Hurdle

  • investors.com

    There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders

  • forbes.com

    Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

  • fool.com

    Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

  • wsj.com

    Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data

  • reuters.com

    Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

  • cnbc.com

    Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

  • prnewswire.com

    Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

  • seekingalpha.com

    Nomura Core Equity Fund Q2 2026 Portfolio Review

  • 247wallst.com

    The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

  • prnewswire.com

    Lilly confirms date and conference call for second-quarter 2026 financial results announcement

  • fool.com

    PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

  • finbold.com

    These major drug stocks rally after Trump's zero tariff announcement